NVS
NVS
US66987V1098
Novartis AG
Loading chart...
Pure Price Volatility Risk (Market Swings)

The business itself is financially solid (Financial Health 67/100, minimal insolvency risk). The high overall score (6/7) is driven primarily by extreme stock price swings (±20.9% p.a.) and steep historical drawdowns.

Volatility Risk

Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.

Volatility Risk Score
6/7 High
6 / 7 SRI Price Fluctuation & Beta

Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Moves noticeably less than the broader market (0.5x).

Beta (Market Relation)
0.47x
Defensive
Volatility (5Y p.a.)
20.9% p.a.
5-Year Horizon
Max Drawdown (5Y)
-20.4%
5-Year Horizon
Sharpe Ratio
0.43
Return / Risk
Speculative / High Risk: Score Basis:

Multi-Horizon Risk & Performance Matrix

Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.

Timeframe
Volatility (p.a.)
Max Drawdown
Sharpe Ratio
Return (p.a.)
1 Year — — — +8.2%
3 Years 21.8% -19.9% 0.51 +13.6%
5 Years 20.9% -20.4% 0.43 +11.6%
10 Years 20.3% -28.6% 0.24 +7.5%

Automated Risk & Health Notes (Red Flags)

Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).

Corporate Governance & ISS Scores

Shareholder rights, board structure and audit safety (Scale 1 = Low Risk, 10 = High Risk)
Overall Governance Risk
-
Audit Risk
-
Board Risk
-
Short Ratio
2.19
ende